MRI Findings in Anti-RNP-Positive MCTD with Myositis
Your cervical spine T2-hyperintense lesions at C3-C5 and cerebellar white-matter hyperintensity most likely represent inflammatory myelopathy and CNS involvement directly related to your anti-RNP-positive mixed connective tissue disease, particularly given your elevated CK, proximal muscle weakness with wasting, and systemic inflammatory markers.
Understanding the Connection
Your clinical picture combines several key features that explain the MRI findings:
Spinal Cord Involvement in MCTD
The cervical T2-hyperintense lesions spanning C3-C5 are consistent with inflammatory myelopathy, which can occur in anti-RNP-positive connective tissue diseases. While the EULAR guidelines primarily address SLE myelopathy, they note that T2-weighted hyperintense lesions on spinal MRI have 70-93% sensitivity for detecting inflammatory cord involvement 1. The involvement of multiple contiguous segments (C3-C5) suggests longitudinal inflammatory involvement rather than compression or ischemia.
Your anti-RNP positivity is particularly relevant here. Anti-U1-RNP antibodies in connective tissue diseases are associated with specific manifestations including Raynaud phenomenon, musculoskeletal involvement, and lung impairment 2. Recent case reports demonstrate that MCTD can present with isolated muscle involvement, including drop head syndrome with myositis findings on cervical MRI and muscle biopsy 3, and even recurrent rhabdomyolysis with CNS manifestations including bilateral VI nerve palsies and aseptic meningitis 4.
Muscle Involvement Correlation
Your elevated CK and proximal muscle weakness with wasting directly correlate with documented MCTD myositis patterns. The 2020 case of DHS in MCTD showed CK elevation with myositis findings on cervical MRI and trapezius muscle biopsy as the only clinical muscle observations 3. Similarly, a 2024 case demonstrated overlap myositis with anti-Ku positivity alongside anti-RNP, presenting with significant muscle involvement 5.
The cervical cord signal changes may reflect:
- Direct inflammatory myelopathy from MCTD
- Extension of inflammatory myositis affecting paraspinal muscles and adjacent cord structures
- Neuroinflammatory processes associated with anti-RNP antibodies
Cerebellar White-Matter Hyperintensity
The cerebellar white-matter changes represent CNS involvement in your MCTD. While less commonly discussed than spinal involvement, CNS manifestations can occur in anti-RNP-positive disease. The EULAR guidelines recommend brain MRI when additional neurological symptoms or signs are present 1, which applies to your restless-leg-type symptoms.
Clinical Implications and Pitfalls
Key Diagnostic Considerations
Exclude other causes of T2 hyperintensity: The differential for spinal T2 hyperintensity is broad, including multiple sclerosis, transverse myelitis, neurosarcoidosis, and cord infarction 6. However, your positive anti-RNP, elevated CK, proximal weakness, and mild CRP elevation create a cohesive picture of MCTD-related inflammatory involvement rather than these alternatives.
Distinguish from compression: Recent research shows that chronic cervical spinal cord compression correlates with T2 hyperintensity through apoptosis and neuroinflammation 7. However, compression typically presents with mechanical symptoms and specific anatomical patterns, which your clinical presentation doesn't suggest.
Management Implications
Based on the EULAR guidelines for neuropsychiatric lupus (applicable to MCTD with CNS/spinal involvement), contrast-enhanced spinal cord MRI is recommended to detect T2-weighted hyperintense lesions and exclude cord compression 1. If you haven't had contrast-enhanced imaging, this should be obtained.
The guidelines indicate that involvement of more than three spinal cord segments indicates longitudinal myelopathy, which may warrant testing for serum NMO IgG (aquaporin) antibodies 1 to exclude co-existing neuromyelitis optica, though your anti-RNP positivity makes primary MCTD more likely.
Treatment Considerations
For inflammatory myelopathy in connective tissue disease, the EULAR guidelines recommend high-dose glucocorticoids combined with intravenous cyclophosphamide if used promptly 1. The case reports show that prednisolone treatment significantly improved myositis 3, and severe cases required high-dose corticosteroids, IVIG, rituximab, and mycophenolate mofetil 5.
Critical pitfall: The guidelines emphasize that relapses are common (50-60%) during corticosteroid dose reduction, underscoring the need for maintenance immunosuppressive therapy 1. Factors associated with severe neurological deficit include extensive spinal cord MRI lesions and delay (>2 weeks) in initiation of therapy 1.
Your Restless-Leg-Type Symptoms
These may represent:
- Peripheral nerve involvement from MCTD
- Manifestation of the cerebellar white-matter changes
- Metabolic factors related to muscle breakdown (elevated CK)
The combination of spinal cord, cerebellar, and peripheral symptoms suggests multifocal nervous system involvement in your MCTD, which is documented but less common than isolated muscle or joint manifestations.
Recommended Next Steps
- Obtain contrast-enhanced cervical and brain MRI to better characterize lesion extent and enhancement patterns
- Consider CSF analysis if not already done, as mild-to-moderate abnormalities occur in 50-70% of inflammatory myelopathy cases 1
- Test for NMO IgG antibodies given the longitudinal nature of your cervical lesions
- Ensure aggressive immunosuppression is initiated promptly if not already started, given the >2-week delay threshold for worse outcomes 1
- Plan for maintenance immunosuppression beyond initial corticosteroid treatment to prevent the 50-60% relapse rate 1